| Medical Mutual | Elahere® (mirvetuximab soravtansine-gynx) (Intravenous) (EOV) | 2025-09-01 |
| Medical Mutual | Fyarro® (sirolimus albumin-bound) (Intravenous) (EOV) | 2025-09-01 |
| Medical Mutual | Ixempra® (ixabepilone) (Intravenous) (EOV) | 2025-09-01 |
| Medical Mutual | Yondelis® (trabectedin) (Intravenous) (EOV) | 2025-09-01 |
| Medical Mutual | Zaltrap® (ziv-aflibercept) (Intravenous) (EOV) | 2025-09-01 |
| Medical Mutual | Ziihera® (zanidatamab-hrii) (Intravenous) (EOV) | 2025-09-01 |
| BCBS Highmark Penn Medicare Advantage | Self-Administered Drug Exclusion List | 2025-08-31 |
| Medicare CGS | Billing and Coding: Wound Application of Cellular and/or Tissue Based Products (CTPs), Lower Extremities (56696) | 2025-08-29 |
| Medicare CGS | Billing and Coding: Transesophageal Echocardiography (TEE) (56809) | 2025-08-29 |
| Medicare CGS | Billing and Coding: Surveillance of Implantable or Wearable Cardioverter Defibrillators (ICDs): Office, Hospital, Web, or Non-Web Based (57038) | 2025-08-29 |